The Goldman Sachs Group, Inc. 13D and 13G filings for Silexion Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-13 11:36 am Purchase | 2025-03-31 | 13G | Silexion Therapeutics Ltd. SLXN | GOLDMAN SACHS GROUP INC GS | 14,130 2.400% | 6,647 (+88.83%) | Filing |
| 2025-02-10 5:31 pm Purchase | 2024-12-31 | 13G | Silexion Therapeutics Ltd. SLXN | GOLDMAN SACHS GROUP INC GS | 7,483 6.600% | 7,483 (New Position) | Filing |